



ImmunoCellular
 Investor Relations Department
 23622 Calabasas Road
 Suite 300
 Calabasas, CA 91302
 United States

[Visit IR website](#)


AMEX: IMUC	
Last Trade:	0.37
Trade Time:	10:41 AM ET July 25, 2017
Change:	-0.01 ↓ (2.237%)
Day Range	0.37 - 0.39
52-Week Range	0.33 - 8.80
Volume	407,034

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular's pipeline includes: a Stem-to-T-cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells; ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; and ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer. ImmunoCellular recently suspended further patient randomization in its p... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- July 18, 2017*
[ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants](#)
- June 29, 2017*
[ImmunoCellular Therapeutics Receives Notice from NYSE MKT for Noncompliance with Continued Listing Standards](#)
- June 21, 2017*
[ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial](#)
- June 12, 2017*
[ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 15, 2017](#)
- June 5, 2017*
[ImmunoCellular Therapeutics Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017](#)

Financials [\[View all \]](#)

- March 9, 2017*
[Annual Report \(10-K\)](#)
- April 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 15, 2017*
[Quarterly Report \(10-Q\)](#)
- November 10, 2016*
[Quarterly Report \(10-Q\)](#)